直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • Life Sciences
    • Transportation and Logistics
  • Experience

Experience

Elan Corp., PLC v. Brightstone Pharma

Elan Corp., PLC

Brightstone Pharma

Represented Elan in Hatch-Waxman litigation against Brightstone and SkyePharma relating to their intention to market generic copies of Naprelan®. Case settled on confidential terms.

Elan Corp., PLC v. Brightstone Pharma, 5:98-cv-00701, E.D.N.C., Judge Britt

Related Professionals

James B. Monroe
Partner
Washington, DC
+1 202 408 4159
Email

Related Practices

Global IP Enforcement, Litigation, and Trials

Branded Hatch-Waxman (ANDA) Litigation and Trials

Related Industries

Life Sciences

Pharmaceutical

Related Experiences

Wyeth v. Osmotica Pharmaceutical Corp.

Wyeth

A high-impact result for R&D licensing programs in the pharmaceutical industry

Elan Corporation PLC

Medtronic PLC v. Masimo Corp.

Medtronic PLC

Wyeth v. Sandoz, Inc.

Wyeth

PQ Corp. v. Johnson Matthey PLC

PQ Corp.

Aventis Pharma, S.A. v. Baxter Healthcare Corp.

Aventis Pharma, S.A.

Synthon Pharmaceuticals, Inc. v. Eli Lilly and Co.

Eli Lilly and Co.; ICOS

Glenmark Generics Ltd. v. GlaxoSmithKline, PLC

GlaxoSmithKline, PLC

Drexler Technology Corp. v. Sony Corp.

Sony Corp.

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP